Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 514.80, up by 4.35 points or 0.85% from its previous closing of Rs. 510.45 on the BSE.

The scrip opened at Rs. 520.00 and has touched a high and low of Rs. 521.55 and Rs. 511.00 respectively. So far 38134 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 564.90 on 28-Aug-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 535.00 and Rs. 493.70 respectively. The current market cap of the company is Rs. 122474.05 crore.

The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.81% and 12.50% respectively.

Sun Pharmaceutical Industries’ wholly-owned Japanese subsidiary has launched ILUMYA Subcutaneous Injection 100 mg Syringe (Nonproprietary name: tildrakizumab (genetical recombination), ILUMYA) in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies.

ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.